Eledon Pharmaceuticals, Inc. (ELDN) earnings
ELDN earnings moved a median of 0.00% by the close. Quarterly and annual ELDN reports and results, each read against the price at its own news timestamp. Back to the ELDN overview →
28 measured ELDN earnings events.
Where these ELDN earnings landedvs 28 measured ELDN earnings reactions
| Middle 50% of ELDN earnings reactions | -1.67% to +1.24% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 ELDN earnings events with a measured close landed between -1.67% and +1.24%; 46% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 | Press release | -0.65% | -4.56% | |
| Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | -0.28% | -1.67% | |
| Form 10-Q Eledon Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.28% | -1.67% | |
| Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | +0.00% | +0.77% | |
| Form 10-Q Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.77% | |
| Form 10-K Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +1.60% | +0.35% | |
| Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results | Press release | -5.00% | -10.00% | |
| Form 10-Q Eledon Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -5.00% | -10.00% | |
| Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results | Press release | +0.00% | +0.00% | |
| Form 10-K/A Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.00% | |
| Form 10-Q Eledon Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-Q/A Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results | Press release | +2.99% | +1.76% | |
| Form 10-Q Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +2.99% | +1.76% | |
| Form 10-K Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +3.12% | +4.15% | |
| Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results | Press release | +0.95% | -9.34% | |
| Form 10-Q Eledon Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.95% | -9.34% | |
| Form 10-K/A Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.35% | +1.06% | |
| Form 10-Q Eledon Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.35% | +1.06% | |
| Form 10-Q/A Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.35% | +1.06% | |
| Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results | Press release | +3.16% | +4.98% | |
| Form NT 10-Q Eledon Pharmaceuticals, For: Jun 30 | SEC filing · Form NT | +3.16% | +4.98% | |
| Form 10-Q Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +7.05% | |
| Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results | Press release | -1.03% | -1.24% | |
| Form 10-K/A Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +14.49% | |
| Form 10-K Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -3.42% | -5.24% | |
| Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results | Press release | +0.00% | -0.85% | |
| Form 10-Q Eledon Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -0.85% |
Keep exploring
More ELDN: analyst actions → · SEC filings → · ELDN overview →